MX2017003878A - Pharmaceutical formulation for reducing bladder spasms and method of use thereof. - Google Patents

Pharmaceutical formulation for reducing bladder spasms and method of use thereof.

Info

Publication number
MX2017003878A
MX2017003878A MX2017003878A MX2017003878A MX2017003878A MX 2017003878 A MX2017003878 A MX 2017003878A MX 2017003878 A MX2017003878 A MX 2017003878A MX 2017003878 A MX2017003878 A MX 2017003878A MX 2017003878 A MX2017003878 A MX 2017003878A
Authority
MX
Mexico
Prior art keywords
bladder spasms
pharmaceutical formulation
reducing bladder
effective amount
reducing
Prior art date
Application number
MX2017003878A
Other languages
Spanish (es)
Inventor
A Dill David
Original Assignee
Wellesley Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellesley Pharmaceuticals Llc filed Critical Wellesley Pharmaceuticals Llc
Publication of MX2017003878A publication Critical patent/MX2017003878A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Abstract

Methods and compositions for reducing bladder spasms are disclosed. The methods comprise administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of acetaminophen and an effective amount of at least one non-steroidal anti¬ inflammatory agent (NSAID). In another embodiment, a method for reducing bladder spasms comprising administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of at least one prostaglandin (PG) pathway inhibitor, wherein the at least one PG pathway inhibitor is not acetaminophen or an NSAID.
MX2017003878A 2014-09-24 2014-09-24 Pharmaceutical formulation for reducing bladder spasms and method of use thereof. MX2017003878A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2014/057200 WO2016048301A1 (en) 2014-09-24 2014-09-24 Pharmaceutical formulation for reducing bladder spasms and method of use thereof

Publications (1)

Publication Number Publication Date
MX2017003878A true MX2017003878A (en) 2017-06-28

Family

ID=55581626

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003878A MX2017003878A (en) 2014-09-24 2014-09-24 Pharmaceutical formulation for reducing bladder spasms and method of use thereof.

Country Status (13)

Country Link
EP (1) EP3197441A4 (en)
JP (1) JP2017532301A (en)
KR (1) KR20170049613A (en)
CN (1) CN107072971A (en)
AU (1) AU2014407186A1 (en)
BR (1) BR112017006141A2 (en)
CA (1) CA2962004A1 (en)
IL (1) IL250827A0 (en)
MX (1) MX2017003878A (en)
RU (1) RU2017113827A (en)
SG (1) SG11201702069XA (en)
WO (1) WO2016048301A1 (en)
ZA (1) ZA201701772B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7025129B2 (en) * 2017-05-17 2022-02-24 小林製薬株式会社 Muscle spasm remedy
WO2019240755A1 (en) * 2018-06-11 2019-12-19 Wellesley Pharmaceuticals, Llc Pharmaceutical compositions and methods for weight loss

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0328060D0 (en) * 2003-12-04 2004-01-07 Sod Conseils Rech Applic Botulinum toxin treatment
AU2006249684A1 (en) * 2005-05-20 2006-11-30 Omeros Corporation Cyclooxygenase inhibitor and calcium channel antagonist compositions and methods for use in urological procedures
CN101460150B (en) * 2006-03-31 2014-02-12 鲁比康研究私人有限公司 Directly compressible composite for orally disintegrating tablets
US20090264530A1 (en) * 2008-04-16 2009-10-22 Nickell Robert P Combined nsaid and acetaminophen formulation and method
US20120010294A1 (en) * 2010-07-08 2012-01-12 Dill David A Compositions and methods for the inhibition of muscle contraction
US9107816B2 (en) * 2011-02-04 2015-08-18 Taris Biomedical Llc Implantable device for controlled dissolution and diffusion of low solubility drug
CN103191430A (en) * 2012-01-04 2013-07-10 韦尔斯利医药有限公司 Sustained release preparation for relieving frequent micturition and application method thereof
AU2012363789B2 (en) * 2012-01-04 2017-04-13 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof

Also Published As

Publication number Publication date
SG11201702069XA (en) 2017-04-27
EP3197441A4 (en) 2018-05-23
EP3197441A1 (en) 2017-08-02
JP2017532301A (en) 2017-11-02
RU2017113827A3 (en) 2018-10-24
AU2014407186A1 (en) 2017-03-09
BR112017006141A2 (en) 2018-02-06
RU2017113827A (en) 2018-10-24
KR20170049613A (en) 2017-05-10
ZA201701772B (en) 2018-08-29
CA2962004A1 (en) 2016-03-31
IL250827A0 (en) 2017-04-30
CN107072971A (en) 2017-08-18
WO2016048301A1 (en) 2016-03-31

Similar Documents

Publication Publication Date Title
CL2017000902A1 (en) Ror-gamma inhibitor dihydropyrrolopyridines
PH12016501668A1 (en) Compositions and methods for the reduction or prevention of hepatic steatosis
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
CL2016001231A1 (en) Autotaxin Inhibitor Compounds
EA201591764A1 (en) OPTIONS OF THE TISSUE INHIBITOR OF METALLOPROTEINASE OF THE THIRD TYPE (TIMP-3), COMPOSITIONS AND METHODS
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
MX2020001756A (en) Benzoquinolone inhibitors of vmat2.
EA201691032A1 (en) IZHOCHROMEN DERIVATIVES AS PHOSFOINOSYTID-3-KINAZ INHIBITORS
WO2014153009A3 (en) Thiosaccharide mucolytic agents
RS54584B1 (en) Compositions comprising 15-hepe and methods of using the same
MX2019001011A (en) Pharmaceutical compounds.
BR112016021034A2 (en) PHARMACEUTICAL COMPOSITION, USE OF SUCH COMPOSITION, METHOD TO TREAT A DISEASE AND KIT
WO2014153495A3 (en) Novel stat3 inhibitors
EP3297674A4 (en) Benzamide and active compound compositions and methods of use
EP3049389A4 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MX2017013137A (en) Chromene derivatives as phoshoinositide 3-kinases inhibitors.
AU2016204294A1 (en) Solid State Forms Of A Quinazoline Derivative And Its Use As A BRAF Inhibitor
BR112014020113A8 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD TO DECREASE URINATION FREQUENCY
DOP2018000066A (en) USEFUL COMPOUNDS TO INHIBIT ROR-GAMMA-T
CL2016001192A1 (en) Use of a dihydroorate dehydrogenase (dhodh) inhibitor to treat neurodegenerative diseases.
BR112016028518A2 (en) pharmaceutical compositions comprising dgla and use thereof
EP3049077A4 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EP3393383A4 (en) Thermal accelerant compositions and methods of use
MX2016016039A (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof.
MX366651B (en) Crystal form alpha of compound a monobenzoate and preparation method thereof and pharmaceutical composition comprising same.